BioSEND requires execution of a Material Transfer Agreement (MTA) prior to shipping samples to any investigator. Per the MTA, the Recipient Investigator must acknowledge the contribution of BioSEND in any and all oral and written presentations, disclosures, and publications resulting from use of samples received from BioSEND using the following language:
NINDS BioSEND grant acknowledgement for all samples obtained from NINDS BioSEND: Samples from the NINDS BioSEND, which receives government support under a cooperative agreement grant (U24 NS095871) awarded by the National Institute of Neurological Disorders and Stroke (NINDS), were used in this study. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible.
Additional language is required if you received samples from one of the following studies:
Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Numbers NS052592 and NS052619 [(Cudkowicz, Mass General Hospital) and (McDermott; Rochester, Coordinating and Biostatistics)], respectively.
The BioFIND Project: Per the BioFIND project Data Use Agreement (see https://www.michaeljfox.org/files/NEWBioFIND%20Data%20Use%20Agreement.pdf): BioFIND is funded by The Michael J. Fox Foundation for Parkinson’s Research and the National Institute Neurological Disorders and Stroke.
Data and biospecimens used in this study were collected via The National Ataxia Foundation funded CRC-SCA consortium (https://www.ataxia.org/crc-sca/). We kindly acknowledge the patients involved in this consortium for their generous contributions to this work.
These samples were collected, in part, via the Early Symptoms of FTLD Study (R01 NS076837).
The NINDS Parkinsons Disease Biomarkers Program (NINDS PDBP): Data and biospecimens used in preparation of this manuscript were obtained from the Parkinson’s Disease Biomarkers Program (PDBP) Consortium, part of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. Investigators include: (please add the names of all investigators found at the following link – https://pdbp.ninds.nih.gov/sites/default/files/assets/policy/PDBP_publication_policy.pdf). The PDBP Investigators have not participated in reviewing the data analysis or content of the manuscript.
Prior to Journal publication the manuscript must be submitted to the PDBP Steering Committee (via PD-Pubs@ninds.nih.gov) who will verify within 5 days that the PDBP is appropriately acknowledged. If this time elapses without notice from the PDBP Steering Committee Representatives, authors may proceed with the paper.
Samples used in this study were in part collected via the PREDICT-HD study (U01 NS082089). All manuscripts submitted, in addition to the appropriate authors, will acknowledge the Predict HD study investigators followed by an asterisk. The asterisk will point to a printed and/or, in a case of an electronic publication, web site http://www.ninds.nih.gov/funding/areas/neurodegeneration/hd_disease/Information-for-Ancillary-Studies.htm (if allowed by the journal) listing the names of Predict HD study investigators.
The READISCA study supported the collection of samples used in this study through National Institute of Neurological Disorders and Stroke (NINDS) grant NS104326. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. The READISCA collection is currently housed at the NINDS BioSEND repository at Indiana University under grant U24NS095871.
Data and samples used in this study were collected in part via the National Institute of Neurological Disorders and Stroke Udall Centers of Excellence in Parkinson’s Disease Program.